1. Oral azole drugs as systemic antifungal therapy;Wood;N. Engl. J. Med.,1994
2. Prolongation of the QT interval related to cisapride-diltiazem interaction;Thomas;Pharmacotherapy,1998
3. Pharmacokinetic and pharmacodynamic consequences of metabolism-based drug interactions with alprazolam, midazolam, and triazolam;Yuan;J. Clin. Pharmacol.,1999
4. Dofetilide, a new class III antiarrhythmic agent;Lenz;Pharmacotherapy,2000
5. European Medicine Agency (2013). European Medicines Agency recommends suspension of marketing authorisation for oral ketoconazole. Retrieved from https://www.ema.europa.eu/en/news/european-medicines-agency-recommends-suspension-marketing-authorisations-oral-ketoconazole.